Cellebrite DI .(CLBT)
Search documents
Cellebrite DI Ltd. (CLBT) is a Great Momentum Stock: Should You Buy?
Zacks Investment Research· 2024-03-07 18:01
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...
Cellebrite Launches FedRAMP Authorization Process to Provide Federal Customers with Enhanced Cloud Security
Newsfilter· 2024-03-07 13:30
TYSONS CORNER, Va. and PETAH TIKVA, Israel, March 07, 2024 (GLOBE NEWSWIRE) -- Cellebrite DI Ltd. (NASDAQ:CLBT), a global leader in Digital Investigative solutions for the public and private sectors, today announced the launch of the process to authorize its software-as-a-service offerings with the Federal Risk and Authorization Management Program (FedRAMP®). The authorization will enable Cellebrite's federal customers to leverage their use of the Company's SaaS solutions, support faster and more cost-effec ...
Haim Shani Concludes Tenure at Cellebrite as Company Enters Next Growth Phase
Newsfilter· 2024-03-06 12:00
TYSONS CORNER, Va. and PETAH TIKVA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- Cellebrite DI Ltd. (NASDAQ:CLBT), a leader in premier Digital Investigative solutions for the public and private sectors, today announced that Haim Shani has retired as a director of the Company, effective immediately. Mr. Shani had been a distinguished member of the Board since 2019, including two years as Chairman from August 2021 until August 2023. Reflecting on his departure, Mr. Shani remarked, "The pace of progress at Celle ...
Are Business Services Stocks Lagging Cellebrite DI Ltd. (CLBT) This Year?
Zacks Investment Research· 2024-02-26 15:41
For those looking to find strong Business Services stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Cellebrite DI Ltd. (CLBT) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Business Services sector should help us answer this question.Cellebrite DI Ltd. is one of 313 companies in the Business Services group. The Business Services group currently sits at #7 within the Zacks Sector Rank. T ...
Surging Earnings Estimates Signal Upside for Cellebrite DI Ltd. (CLBT) Stock
Zacks Investment Research· 2024-02-20 18:21
Cellebrite DI Ltd. (CLBT) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.Analysts' growing optimism on the earnings prospects of this company is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock ...
Cellebrite DI Ltd. (CLBT) Is Up 20.78% in One Week: What You Should Know
Zacks Investment Research· 2024-02-19 18:00
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even though momentum is a popular stock char ...
Cellebrite DI .(CLBT) - 2023 Q4 - Earnings Call Transcript
2024-02-15 17:01
Financial Data and Key Metrics - Q4 revenue grew 26% YoY to $93 million, driven by a 26% increase in subscription software revenue [19] - Adjusted EBITDA for Q4 was $22.27 million, representing a 24% margin [19] - Non-GAAP EPS for Q4 was $0.11 [19] - Cash and investments at the end of 2023 totaled $332 million, a 62% increase from the end of 2022 [19] - Full-year 2023 revenue increased 20% to $325.1 million, with subscription revenue growing 30% [152] - Full-year adjusted EBITDA was $61.9 million, representing a 19% margin [38] - ARR grew 27% YoY to $315.7 million in Q4 and $316 million for the full year [19][60] Business Line Performance - Subscription revenue accounted for 85% of total revenue in 2023, with perpetual license revenue declining 36% [152] - Cloud-based revenue grew rapidly in 2023, though it represented less than 10% of total revenue [12] - Pathfinder deals reached a record number in Q4, with approximately 200 agencies now using the solution [27] - Inseyets, a new solution, has seen strong interest, with upgrades contributing to a 65% ARR increase at one national police force [52] Market Performance - Americas accounted for 53% of total ARR in 2023, followed by EMEA at 36% and Asia-Pacific at 11% [36] - ARR growth in the Americas was 30%, EMEA grew 23%, and Asia-Pacific increased 29% [36] - A large deal with a Western European national police force grew ARR by more than 25% [22] Strategy and Industry Competition - The company is focusing on expanding its Case-to-Closure (C2C) platform, which integrates digital forensic and investigative tools [18][26] - Investments in cloud infrastructure and FedRAMP certification are expected to open up more federal opportunities [25] - The company plans to scale its SaaS offerings, including cloud-enabling previously on-prem solutions and developing cloud-native offerings [25] - Inseyets is positioned as a game-changer, enabling customers to complete examinations up to twice as fast as before [9] Management Commentary on Operating Environment and Future Outlook - The company expects Q1 2024 revenue to range between $83 million and $88 million, representing 17% to 24% YoY growth [41] - Full-year 2024 revenue is expected to range from $370 million to $385 million, with ARR targets between $380 million and $400 million [153] - Adjusted EBITDA for 2024 is anticipated to be between $70 million and $80 million, with margins of 19% to 21% [42] - The company is optimistic about improving profitability and expects higher adjusted EBITDA margins in the second half of 2024 [42] Other Important Information - The company plans to expand its workforce by approximately 15% in 2024, focusing on go-to-market and innovation initiatives [13] - FedRAMP certification is a key milestone expected to unlock additional federal opportunities [119][120] - The company is exploring inorganic growth opportunities, including technological tuck-ins and larger acquisitions [112] Q&A Summary Question: Inseyets Pricing and Productivity Impact - Inseyets is priced 20% to 25% higher than legacy solutions, with additional modules contributing to higher value [104] - The company expects Inseyets to drive significant growth, with upgrades and add-on modules contributing to ARR expansion [20][24] Question: Subscription Revenue Benchmark - Subscription revenue is expected to remain around 85% of total revenue, with perpetual licenses becoming negligible [81][142] Question: Pathfinder and Guardian Contribution - Pathfinder and Guardian are emerging growth engines, with Pathfinder deals growing significantly in Q4 [27][90] - Both solutions are expected to grow faster than the core Inseyets offering, contributing to ARR growth in 2024 [106] Question: FedRAMP Market Opportunity - FedRAMP certification is expected to double the company's federal business by enabling access to additional buying centers [132] Question: Training and Customer Adoption - Training is essential for customer adoption, especially in law enforcement, and is integrated into the company's post-sale customer experience strategy [78][89] Question: M&A Strategy - Inorganic growth is part of the company's long-term strategy, with potential targets being evaluated [112] Question: Competitive Pricing Dynamics - The company operates in a value-based market, with competitors also increasing prices systematically [115]
Cellebrite DI .(CLBT) - 2023 Q4 - Earnings Call Presentation
2024-02-15 14:27
Financial Highlights - Total Revenue for Q4 2023 reached $93 million, a 26% increase compared to $74 million in Q4 2022[16, 43] - Subscription Revenue for Q4 2023 was $79 million, also a 26% increase from the previous year[18, 44] - Annual Recurring Revenue (ARR) as of December 2023 reached $316 million, a 27% increase compared to December 2022's $249 million[18] - Adjusted EBITDA for Q4 2023 was $23 million, representing 24% of revenue, compared to $16 million in Q4 2022[18] - Cash and cash equivalents, short-term and long-term marketable securities were $331.8 million as of December 31, 2023[59] Growth Drivers - Revenue growth is primarily driven by subscription services[42] - ARR growth is fueled by expansion within the existing customer base[52] Financial Forecast - The company anticipates ARR between $325 million and $335 million for Q1 2024 and between $380 million and $400 million for FY 2024[75] - Revenue is projected to be between $83 million and $88 million for Q1 2024 and between $370 million and $380 million for FY 2024[75] - Adjusted EBITDA is expected to be between $12 million and $15 million for Q1 2024 and between $70 million and $80 million for FY 2024[75]
Cellebrite: Growth, Profits, And Consistency
Seeking Alpha· 2024-02-14 20:15
Busakorn Pongparnit/Moment via Getty Images Introduction Cellebrite DI Ltd. (NASDAQ:CLBT) is an Israeli company that specializes in digital forensics data extraction, analytics and management. Their primary digital forensics software product, Inseyets (launched in January 2024), allows law enforcement to connect its software to a mobile device like a cell phone or tablet and securely access the device and extract data from it. The data is then decoded, reviewed, shared and analyzed with different products i ...
Cellebrite DI .(CLBT) - 2024 Q1 - Quarterly Report
2024-02-14 16:00
● GAAP gross profit and gross margin of $78.1 million and 84.0%, respectively; Non-GAAP gross profit and gross profit margin of $78.6 million and 84.5%, respectively Full-Year 2023 Financial Highlights ● GAAP net loss of $81.1 million; Non-GAAP net income of $60.9 million Innovation · In mid-November 2023, Cellebrite sponsored and participated in Milipol, the preeminent global law enforcement and homeland security event held in Paris. Supplemental financial information can be found on the Investor Relations ...